6E62 image
Entry Detail
PDB ID:
6E62
Keywords:
Title:
Crystal structure of malaria transmission-blocking antigen Pfs48/45 6C in complex with antibody 85RF45.1
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2018-07-23
Release Date:
2018-11-28
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.27
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:85RF45.1 Fab heavy chain
Chain IDs:B (auth: H), E (auth: B)
Chain Length:222
Number of Molecules:2
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Description:85RF45.1 Fab light chain
Chain IDs:C (auth: L), F (auth: C)
Chain Length:216
Number of Molecules:2
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Description:Pf48/45
Chain IDs:A (auth: P), D (auth: A)
Chain Length:139
Number of Molecules:2
Biological Source:Plasmodium falciparum
Primary Citation
Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.
Nat Commun 9 4458 4458 (2018)
PMID: 30367064 DOI: 10.1038/s41467-018-06742-9

Abstact

Interventions that can block the transmission of malaria-causing Plasmodium falciparum (Pf) between the human host and Anopheles vector have the potential to reduce the incidence of malaria. Pfs48/45 is a gametocyte surface protein critical for parasite development and transmission, and its targeting by monoclonal antibody (mAb) 85RF45.1 leads to the potent reduction of parasite transmission. Here, we reveal how the Pfs48/45 6C domain adopts a (SAG1)-related-sequence (SRS) fold. We structurally delineate potent epitope I and show how mAb 85RF45.1 recognizes an electronegative surface with nanomolar affinity. Analysis of Pfs48/45 sequences reveals that polymorphisms are rare for residues involved at the binding interface. Humanization of rat-derived mAb 85RF45.1 conserved the mode of recognition and activity of the parental antibody, while also improving its thermostability. Our work has implications for the development of transmission-blocking interventions, both through improving vaccine designs and the testing of passive delivery of mAbs in humans.

Legend

Protein

Chemical

Disease

Primary Citation of related structures